Clorazepate dipotassium
Clorazepate Dipotassium, Tranxene (clorazepate dipotassium) is a small molecule pharmaceutical. Clorazepate dipotassium was first approved as Tranxene on 1982-01-01. It is used to treat alcohol withdrawal delirium, anxiety disorders, and partial epilepsies in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Clorazepate dipotassium, Tranxene (discontinued: Clorazepate dipotassium, Gen-xene, Tranxene)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Clorazepate dipotassium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRANXENE | Key Therapeutics | N-017105 RX | 1982-01-01 | 1 products, RLD |
Show 3 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clorazepate dipotassium | ANDA | 2024-10-28 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycoses | D009181 | — | B35-B49 | — | — | — | 1 | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | — | — | 1 | — | 1 |
| T-cell lymphoma | D016399 | — | — | — | — | — | 1 | — | 1 |
| T-cell lymphoma peripheral | D016411 | — | — | — | — | — | 1 | — | 1 |
| Mycosis fungoides | D009182 | — | C84.0 | — | — | — | 1 | — | 1 |
| T-cell lymphoma cutaneous | D016410 | — | — | — | — | — | 1 | — | 1 |
| Depression | D003863 | — | F33.9 | — | — | — | 1 | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | 1 | — | — | 1 |
| Headache | D006261 | HP_0002315 | R51 | — | — | 1 | — | — | 1 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | 1 | — | — | 1 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | 1 | — | — | 1 |
| Emergencies | D004630 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Clorazepate dipotassium |
| INN | dipotassium clorazepate |
| Description | Clorazepic acid is a 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively. It has a role as a prodrug, an anticonvulsant, an anxiolytic drug and a GABA modulator. It is a conjugate acid of a clorazepic acid anion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-] |
Identifiers
| PDB | — |
| CAS-ID | 57109-90-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2096631 |
| ChEBI ID | 3762 |
| PubChem CID | 2809 |
| DrugBank | DB00628 |
| UNII ID | 63FN7G03XY (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 287 documents
View more details
Safety
Black-box Warning
Black-box warning for: Clorazepate dipotassium
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,512 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use